Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply

被引：0

作者：

Hamatani, Tatsuto ^{[1
]}

Fukudo, Shin ^{[2
]}

Nakada, Yosuke ^{[1
]}

Inada, Hiroshi ^{[1
]}

Kazumori, Kiyoyasu ^{[1
]}

Miwa, Hiroto ^{[3
]}

机构：

[1] Sumitomo Dainippon Pharma Co Ltd, Osaka, Japan

[2] Tohoku Univ, Grad Sch Med, Dept Behav Med, Sendai, Miyagi, Japan

[3] Hyogo Coll Med, Dept Internal Med, Div Gastroenterol, Nishinomiya, Hyogo, Japan

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 52卷 / 07期

关键词：

IRRITABLE-BOWEL-SYNDROME; OTILONIUM BROMIDE; DOUBLE-BLIND; EFFICACY; CONSTIPATION; LINACLOTIDE; EVALUATE; 12-WEEK;

D O I：

10.1111/apt.16047

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1239 / 1240

页数：2

共 50 条

[41] Comparative efficacy trials with no placebo group cannot determine efficacy Authors' reply to Lin and colleagues
Cohen, Steven P.
Vorobeychik, Yakov
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
[42] Intent-to-Randomize Corrections for Missing Data Resulting from Run-In Selection Bias in Clinical Trials for Chronic Conditions
Berger, Vance W.
Vali, Behrang
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (02) : 263 - 270
[43] Placebo-controlled trials are unethical in clinical hypertension research - In reply
Preston, RA
Materson, BJ
Reda, DJ
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (20) : 3168 - 3169
[44] Neuroprotective agents for clinical trials in ALS: A systematic assessment - Reply from the authors
Traynor, B. J.
Bruijn, L.
Conwit, R.
Beal, F.
O'Neill, G.
Fagan, S. C.
Cudkowicz, M. E.
NEUROLOGY, 2007, 68 (09) : 710 - 710
[45] Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?
Frost, Chris
Kenward, Michael G.
Fox, Nick C.
STATISTICS IN MEDICINE, 2008, 27 (19) : 3717 - 3731
[46] Letter: multivariate clinical model for eosinophilic oesophagitis - is this generalisable to a general population? Authors' reply
von Arnim, U.
Roehl, F. W.
Miehlke, S.
Jechorek, D.
Reinhold, D.
Wex, T.
Malfertheiner, P.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (06) : 861 - 861
[47] Authors reply: Response to the editorial titled "BVS, RDN, IABP: The Afghanistan of interventional clinical trials" Reply
Mishra, Sundeep
INDIAN HEART JOURNAL, 2018, 70 (03) : 462 - 462
[48] Letter: Lactobacillus rhamnosus GG offers no benefit over placebo in children with acute gastroenteritis. Authors' reply
Szajewska, Hania
Kolodziej, Maciej
Shamir, Raanan
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (05) : 622 - 623
[49] ETHICS OF PLACEBO-CONTROLLED CLINICAL TRIALS IN MULTIPLE SCLEROSIS: A REASSESSMENT Reply
Polman, Chris H.
NEUROLOGY, 2009, 72 (13) : 1192 - 1192
[50] Reply to the letter to the editor "Controlled clinical trials and efficacy: Report of a neurosurgical study"
Ruiz-Juretschke, F.
Gonzalez-Quarante, L. H.
NEUROLOGIA, 2020, 35 (02): : 137 - 138

← 1 2 3 4 5 →